| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Lamb Lawrence | EVP and CSO | C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK | /s/ Jason Minio, Attorney-in-Fact | 07 May 2025 | 0001830059 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INAB | Series B Warrants (right to buy) | Disposed to Issuer | -1,639 | -100% | 0 | 27 Apr 2025 | Common Stock | 1,639 | $1.50 | Direct | F1, F2, F3 | ||
| transaction | INAB | Series B Warrants (right to buy) | Award | +1,639 | 1,639 | 27 Apr 2025 | Common Stock | 1,639 | $0.4500 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. |
| F2 | Fully vested and exercisable. |
| F3 | The reported securities are included within 1,639 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 1,639 shares of common stock. |